Scarica l'app Stockscreener
173.25
2.47%
4.17
Pre-mercato:
173.00
-0.25
-0.14%
Precedente Chiudi:
$169.08
Aprire:
$170.1
Volume 24 ore:
2.00M
Relative Volume:
1.17
Capitalizzazione di mercato:
$23.25B
Reddito:
$1.08B
Utile/perdita netta:
$-433.19M
Rapporto P/E:
-50.95
EPS:
-3.4004
Flusso di cassa netto:
$-225.09M
1 W Prestazione:
+6.56%
1M Prestazione:
-2.26%
6M Prestazione:
+95.76%
1 anno Prestazione:
+144.53%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$158.68
$175.08
Portata 52W:
$68.02
$191.05
Guardant Health Inc Stock (GH) Company Profile
Nome
Guardant Health Inc
Settore
Industria
Telefono
855-698-8887
Indirizzo
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
173.25 | 23.25B | 1.08B | -433.19M | -225.09M | -3.4004 |
TMO
Thermo Fisher Scientific Inc
|
684.89 | 253.24B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.97 | 163.77B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
404.90 | 58.36B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.96 | 49.61B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
273.60 | 45.03B | 16.63B | 1.39B | 2.12B | 8.0674 |
Guardant Health Inc Stock (GH) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-23 | Iniziato | Roth Capital | Buy |
| 2026-09-09 | Ripresa | UBS | Buy |
| 2026-09-08 | Iniziato | Rothschild & Co Redburn | Buy |
| 2026-06-26 | Ripresa | Bernstein | Outperform |
| 2026-06-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-06-05 | Iniziato | Goldman | Buy |
| 2026-06-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-06-02 | Ripresa | Wolfe Research | Outperform |
| 2026-02-20 | Reiterato | Canaccord Genuity | Buy |
| 2026-02-17 | Iniziato | Robert W. Baird | Outperform |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-12-02 | Ripresa | Morgan Stanley | Overweight |
| 2025-09-25 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | Ripresa | Wells Fargo | Overweight |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-28 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-24 | Ripresa | Craig Hallum | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Neutral |
| 2023-12-13 | Iniziato | Wolfe Research | Peer Perform |
| 2023-11-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-26 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2023-01-05 | Iniziato | Scotiabank | Sector Outperform |
| 2022-11-01 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | Iniziato | Craig Hallum | Buy |
| 2022-10-06 | Iniziato | Stephens | Overweight |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Overweight |
| 2022-04-28 | Ripresa | BTIG Research | Buy |
| 2022-02-24 | Reiterato | Canaccord Genuity | Buy |
| 2022-02-24 | Reiterato | Citigroup | Buy |
| 2022-02-24 | Reiterato | Cowen | Outperform |
| 2022-02-24 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-24 | Reiterato | SVB Leerink | Outperform |
| 2022-02-24 | Reiterato | Stifel | Buy |
| 2022-02-24 | Reiterato | Wells Fargo | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-11 | Iniziato | Stifel | Buy |
| 2020-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2020-06-12 | Iniziato | BTIG Research | Buy |
| 2020-02-21 | Iniziato | Guggenheim | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-08-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-04-16 | Iniziato | Canaccord Genuity | Buy |
| 2019-04-10 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | Reiterato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | BofA/Merrill | Neutral |
| 2018-10-29 | Iniziato | JP Morgan | Overweight |
| 2018-10-29 | Iniziato | William Blair | Outperform |
Mostra tutto
Guardant Health Inc Borsa (GH) Ultime notizie
Form 4 Guardant Health Inc: Roberto Mignone (Director) For: 21 October - Investing.com Nigeria
Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research
Guardant Health director Tariq Musa sells $19,242 in stock By Investing.com - Investing.com South Africa
Form 4 Guardant Health Inc: Medina Manuel Hidalgo (Director) For: 17 October - Investing.com Nigeria
Form 4 Guardant Health Inc: Medina Manuel Hidalgo (Director) For: 17 October - Investing.com Canada
Guardant Health director Tariq Musa sells $19,242 in stock - Investing.com
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)? - Zacks Investment Research
Director Tariq Musa proposes selling 116 Guardant Health (GH) shares. - Stock Titan
Guardant Health director Alex M. Azar II sells $11,032 in stock By Investing.com - Investing.com South Africa
Form 4 Guardant Health Inc: Alex M. Azar II (Director) For: 14 October By Investing.com - Investing.com South Africa
Guardant Health director Alex M. Azar II sells $11,032 in stock - Investing.com
Guardant Health director Alex M. Azar II sells $11,032 in stock - Investing.com Canada
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Zacks Investment Research
A director proposes selling 69 Guardant Health (GH) shares valued at $11,032. - Stock Titan
Form 4 Guardant Health Inc: Alex M. Azar II (Director) For: 12 October - Investing.com Canada
Form 4 Guardant Health Inc: Alex M. Azar II (Director) For: 12 October - Investing.com Nigeria
Form 4 Guardant Health Inc: Helmy Eltoukhy (Director, Co-Chief Executive Officer) For: 30 September - Investing.com Canada
Form 4 Guardant Health Inc: Helmy Eltoukhy (Director, Co-Chief Executive Officer) For: 30 September - Investing.com Nigeria
Julia Letlow Stock Trades and Disclosures - TechGraph
Form 4 Guardant Health Inc For: 22 September By Investing.com - Investing.com Canada
Form 4 Guardant Health Inc For: 22 September By Investing.com - Investing.com Nigeria
Form 4 Guardant Health Inc For: 22 September By Investing.com - Investing.com UK
Director Steve Krognes Sells 6,674 Shares of Guardant Health Inc (GH) - GuruFocus
Guardant Health (GH) director plans new stock sale - Stock Titan
Guardant Health (NASDAQ: GH) director may sell $144K in equity-comp stock - Stock Titan
Guardant Health (NASDAQ: GH) director moves to sell 6,674 shares - Stock Titan
Officer at Guardant Health (NASDAQ: GH) plans sale of 7,738 shares under Rule 144 - Stock Titan
Guardant Health CIO Kumud Kalia sells $632k in stock - Investing.com
Guardant Health Inc Share PriceGH, RNS News, Articles, Quotes, & Charts - Proactive financial news
Guardant Health (NASDAQ: GH) officer moves to sell more stock - Stock Titan
(GH) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bernstein reiterates Guardant Health stock rating on margin outlook - Investing.com
Bernstein reiterates Guardant Health stock rating on margin outlook By Investing.com - Investing.com Canada
Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer - BioSpace
GH Maintained by UBS -- Price Target Raised to $225 - GuruFocus
Guardant Health and Collaborators Present 20 Abstracts Showcasing Advances in Liquid Biopsy Tests and Methylation-Based Tumor Classification for Lung Cancer At 2026 World Conference on Lung Cancer - marketscreener.com
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
Business Insider Names Guardant Health One of America's Most Innovative Businesses - Business Wire
GH Initiates Coverage On Guardant Health -- Buy Rating by Rothsc - GuruFocus
What Makes Guardant Health (GH) a Compelling Bet? - Yahoo Finance
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com Canada
Rothschild Redburn initiates Guardant Health stock with buy rating By Investing.com - Investing.com India
Rothschild Redburn initiates Guardant Health stock with buy rating - investing.com
Rothschild Redburn initiates Guardant Health stock with buy rating - Investing.com
AstraZeneca Secures FDA Nod for New Breast Cancer Therapy Etcamah - Zacks Investment Research
Guardant Health, Inc. (GH) Stock Analysis: Unveiling a 20% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
Guardant Health Leads the Way in Blood-Based Single Cancer Screening - Morningstar
Guardant Health Stock Price Forecast. Should You Buy GH? - StockInvest.us
GH Looks 144.6% Overvalued on GF Value™ - GuruFocus
Guardant Health Faces a $245 Million Patent Judgment, But Its Newer Tests Could Offer Protection - Yahoo Finance
Guardant Health Inc Azioni (GH) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Guardant Health Inc Azioni (GH) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hidalgo Medina Manuel | Director |
Oct 17 '26 |
Option Exercise |
0.00 |
232 |
0 |
5,252 |
| Tariq Musa | Director |
Oct 16 '26 |
Proposed Sale |
165.88 |
116 |
19,242 |
0 |
| Tariq Musa | Director |
Oct 16 '26 |
Sale |
165.88 |
116 |
19,242 |
11,583 |
| Tariq Musa | Director |
Oct 15 '26 |
Option Exercise |
0.00 |
250 |
0 |
11,699 |
| Azar Alex M II | Director |
Oct 14 '26 |
Proposed Sale |
159.88 |
69 |
11,032 |
0 |
| Azar Alex M II | Director |
Oct 14 '26 |
Sale |
159.89 |
69 |
11,032 |
893 |
| Azar Alex M II | Director |
Oct 12 '26 |
Option Exercise |
0.00 |
137 |
0 |
962 |
| Kalia Kumud | Chief Information Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
6,046 |
0 |
45,840 |
| Monroe Terilyn J. | Chief People Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
4,019 |
0 |
26,998 |
| Saia John G. | Chief Legal Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
7,063 |
0 |
46,054 |
0.29%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):